Review Article

The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Table 1

Baseline characteristics of the included studies.

StudyRegionStudy
design
⁢Number of patientsHBV DNA
log 10 copies/mL
HBeAg-positivePTA (%) or INR (means ± SD)TBIL (means ± SD) (%)ALB (means ± SD) (%)ALT (means ± SD) (%) Treatment
duration (months)
ETVLAMETVLAMETVLAMETVLAMETVLAMETVLAMETVLAM

Hu et al., 2010 [25]⁢China⁢cohort90908.2 ± 18.2 ± 1NANANANANANANANANANA6

Gao et al., 2015 [26]⁢China⁢cohort4666NANANANANANANANANANANANA24

Cui et al., 2010 [22]⁢China⁢cohort33345.9 ± 1.55.9 ± 1.510132.27 ± 0.552.61 ± 1.0320.10 ± 11.2419.91 ± 8.5633.36 ± 4.4331.64 ± 5.32364 (47–2861)226.5 (22–2314)3

Chen et al., 2012 [27]⁢China⁢cohort42307.04 ± 1.67.25 ± 0.89NANA34.88 ± 12.2732.18 ± 11.44326.29 ± 201.35332.65 ± 182.6531.45 ± 5.7929.59 ± 5.63324.19 ± 310.04287.61 ± 261.503

Lai et al., 2013 [28]⁢China⁢cohort9389NANANANANANANANANANANaNA3

Zhang et al., 2014 [21]⁢China⁢cohort65547 ± 1.47.2 ± 1.6212324.7 ± 6.025.1 ± 5.7331.6 ± 74.8320.1 ± 82.428.7 ± 6.929.4 ± 5.3352.5 ± 77.2345.2 ± 89.513

Wen et al., 2010 [19]⁢China⁢RCT4647NANANANA29.8 ± 8.530.6 ± 9.1375.2 ± 200.3389.4 ± 198.131.4 ± 4.632.7 ± 3.9402.5 ± 292.7395.8 ± 297.412

Cai and Shi, 2011 [29]⁢China⁢RCT3834NANANANA34.6 ± 8.134.8 ± 9.6256.5 ± 137.4257.6 ± 135.931.4 ± 4.632.8 ± 4.5395.4 ± 235.3387.1 ± 245.412

He, 2013 [30]⁢China⁢RCT57576.2 ± 2.16.1 ± 1.9NANA30 ± 830 ± 8339 ± 135342 ± 14831 ± 631 ± 6399 ± 245404 ± 2376

Yuan, 2015 [31]⁢China⁢RCT149148NANANANA33.89 ± 7.7833.96 ± 7.80260.41 ± 140.11260.38 ± 140.1031.88 ± 6.1131.89 ± 6.10396.51 ± 240.12397.00 ± 240.2212

ETV: entecavir; LAM: lamivudine; NA: not available; PTA: prothrombin activity; INR: international standard ratio; TBIL: total bilirubin; ALB: albumin; ALT: alanine aminotransferase; RCT: randomized controlled studies.